These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27311461)

  • 1. Modeling Pharmacokinetics.
    Bois FY; Brochot C
    Methods Mol Biol; 2016; 1425():37-62. PubMed ID: 27311461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBPK Modeling to Simulate the Fate of Compounds in Living Organisms.
    Bois FY; Tebby C; Brochot C
    Methods Mol Biol; 2022; 2425():29-56. PubMed ID: 35188627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan.
    Beaudouin R; Micallef S; Brochot C
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):103-16. PubMed ID: 20122977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating parameter availability for physiologically based pharmacokinetic (PBPK) modeling of perfluorooctanoic acid (PFOA) in zebrafish.
    Khazaee M; Ng CA
    Environ Sci Process Impacts; 2018 Jan; 20(1):105-119. PubMed ID: 29265128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational toxicology: application in environmental chemicals.
    Tan YM; Conolly R; Chang DT; Tornero-Velez R; Goldsmith MR; Peterson SD; Dary CC
    Methods Mol Biol; 2012; 929():9-19. PubMed ID: 23007424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.
    Lipscomb JC; Haddad S; Poet T; Krishnan K
    Adv Exp Med Biol; 2012; 745():76-95. PubMed ID: 22437814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An introduction to physiologically-based pharmacokinetic models.
    Upton RN; Foster DJ; Abuhelwa AY
    Paediatr Anaesth; 2016 Nov; 26(11):1036-1046. PubMed ID: 27550716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary regional PBPK model of lung metabolism for improving species dependent descriptions of 1,3-butadiene and its metabolites.
    Campbell J; Van Landingham C; Crowell S; Gentry R; Kaden D; Fiebelkorn S; Loccisano A; Clewell H
    Chem Biol Interact; 2015 Aug; 238():102-10. PubMed ID: 26079054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in methodology of establishing physiologically based pharmacokinetic models].
    Jin YW; Ma YM
    Yao Xue Xue Bao; 2014 Jan; 49(1):16-22. PubMed ID: 24783500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation.
    Thiel C; Schneckener S; Krauss M; Ghallab A; Hofmann U; Kanacher T; Zellmer S; Gebhardt R; Hengstler JG; Kuepfer L
    J Pharm Sci; 2015 Jan; 104(1):191-206. PubMed ID: 25393841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic model for quinocetone in pigs and extrapolation to mequindox.
    Zhu X; Huang L; Xu Y; Xie S; Pan Y; Chen D; Liu Z; Yuan Z
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2017 Feb; 34(2):192-210. PubMed ID: 28001497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.